GLP-1 Medications Show Promising Mental Health Benefits for Individuals with Obesity

While GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) like semaglutide and tirzepatide are primarily prescribed for weight loss and managing metabolic diseases such as type 2 diabetes, their impact on broader aspects of patient well-being, particularly mental health, is an area of growing interest. Many individuals with obesity also experience co-occurring psychiatric symptoms and eating disorder behaviors, which can significantly impair their quality of life. This study aimed to investigate whether GLP-1 treatment for obesity is associated with improvements in mental health, eating disorder symptoms, and overall health-related quality of life.

Across the six-month treatment period, participants consistently reported a pattern of significant improvements in several key areas. Mental health scores showed statistically significant improvements, indicating a positive impact on psychological well-being. Furthermore, there were statistically significant reductions in the severity of eating disorder symptoms, suggesting a beneficial effect on disordered eating behaviors. Participants also experienced statistically significant enhancements in their overall health-related quality of life. This included notable improvements in specific domains such as reduced pain interference and better sleep quality. These findings suggest that the benefits of GLP-1 medicines extend beyond metabolic control. The study observed statistically significant improvements across multiple domains, including mental health, eating disorder symptoms, and health-related quality of life, over six months of GLP-1 treatment.